A Phase 2 interventional study of HDM1002 100 mg QD and HDM1002 200 mg QD 12weeks in Overweight and Obesity, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-15.
Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Obesity by Huadong Medicine Co., Ltd. — 10 open to participants now, 11 under way, 5 of them phase 3. Obesity · Huadong Medicine Co., Ltd..
Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., this one is the 8th largest by planned enrollment, is one of 3 that started in 2024, is one of 3 in phase 2, reaches primary completion later than 0 of the 10 other live ones, and was the 3rd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →10 of the 13 studies in Obesity by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2024; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 200 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., one of the names counted as Huadong Medicine Co., Ltd.. Under that name alone:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Obesity by Huadong Medicine Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502001Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | 2026-12-01 |
| NCT07521631Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | 2027-02-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
This multicenter, randomized, double-blind, placebo-controlled phase II clinical trial aims to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults. Participants with a BMI between 24 and 40 will be include. A total of 180 participants will be randomized in a 1:1:1:1 ratio to receive different doses of HDM1002 or placebo. Following the screening period to confirm eligibility up to 2-weeks, the study will consist of a treatment period will be 12 weeks, followed by an approximate 4-week follow-up.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's planned enrollment of 180 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥28 but \< 40.0 kg/m2 at screening or randomization,or BMI≥24.0 kg/m2 but \< 28 kg/m2 with any of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HDM1002 tablets 100mg twice daily, 12weeks
Drug: HDM1002 100 mg QD
HDM1002 tablets 200mg twice daily, 12weeks
Drug: HDM1002 200 mg QD 12weeks
HDM1002 tablets 400mg once daily, 12weeks
Drug: HDM1002 400 mg QD 12weeks
Matching placebo will be provided, 12weeks
Drug: Placebo
HDM1002 tablets 100mg daily, 12weeks
Also known as: HDM1002
HDM1002 tablets 200mg daily, 12weeks
Also known as: HDM1002
HDM1002 tablets 400mg daily, 12weeks
Also known as: HDM1002
Matching placebo will be provided
Percentage Change From Baseline in Body Weight at Week 12
Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 12
Percentage Change From Baseline in Body Weight at Week 2, Week 4, Week 6, Week 8, Week 10
Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10
Percentage Change of Participants Achieving Weight Loss ≥ 5% and ≥ 10% at Week 12
Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.
Time frame: Baseline, Week 12
Change From Baseline in Body Mass Index (BMI), And Waist Circumference
BMI was recorded in kg/m2, and Waist Circumference was recorded in cm
Time frame: Baseline, Week 12
Percentage change from baseline in fasting lipid profile (total cholesterol, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, non HDL cholesterol, lipoprotein (a) (Lp[a]), triglycerides)
Fasting Lipid Profiles were measured at planned time points.
Time frame: Baseline, Week 12
Change From Baseline in Systolic and Diastolic Blood Pressure
Blood Pressure was measured using an automated device
Time frame: Baseline, Week 12
Number of Participants with Clinical Laboratory Abnormalities, and Abnormalities in Vital Signs, Physical Examination and Electrocardiogram and Number of Participants With Treatment Emergent Adverse Events
Vital signs (blood pressure, pulse rate, body temperature, respiratory rate), physical examination, ECG and clinical laboratory evaluations (hematology, clinical chemistry, coagulation, urinalysis, calcitonin, serum amylase and lipase)
Time frame: Through Week 16]
Change From Baseline in Fasting Insulin
The fasting plasma glucose measures the levels of Fasting Insulin were measured at planned time points
Time frame: Time Frame: Baseline, Week 12
Change From Baseline in Fasting plasma Glucose
The fasting plasma glucose measures the levels of glucose in the bloodFasting Insulin were measured at planned time points
Time frame: Time Frame: Baseline, Week 12
Change From Baseline in Fasting C-Peptide,
The fasting plasma glucose measures the levels of C-Peptide were measured at planned time points
Time frame: Time Frame: Baseline, Week 12
Change From Baseline in HbA1c at Week 12
HbA1c can be used as a diagnostic test for diabetes and is a widely recognized objective measure of glycemic control
Time frame: Time Frame: Baseline, Week 12
Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)
Area under the curve from time 0 to 24 h(AUC0-24h)
Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85
Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)
Maximum plasma concentration (Cmax),
Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85
Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)
Minumum plasma concentration (Cmin)
Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85
Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)
Time to maximum plasma concentration (Tmax)
Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85
Pharmacokinetic (PK) Profiles of HDM1002 and Its Metabolites (If Feasible)
AUCtau
Time frame: Day 1, Day 15, Day 29, Day 57 and Day 85
No study locations are listed for this record.
Start is estimated for Jul 2024; primary completion for Oct 2024, 3 months later.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 3 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HDM1002
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. →